Sign Out
Traceability: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Serious hypersensitivity: Serious hypersensitivity reactions including cases of anaphylaxis, angioedema and urticaria have been reported. If a serious hypersensitivity reaction occurs, administration of galcanezumab should be discontinued immediately and appropriate therapy initiated.
Excipients: This medicinal product contains less than 1 mmol sodium (23 mg) per 120 mg dose, i.e., is essentially "sodium-free".
Effects on ability to drive and use machines: Galcanezumab may have a minor influence on the ability to drive and use machines. Vertigo may occur following the administration of galcanezumab (see Adverse Reactions).
Continue with Google